News

PipelineReview.com4h

Response Pharmaceuticals Announces Positive Top-Line Results From Phase 2 Study of RDX-002 in Post-GLP-1 Management

Novel Mechanism Demonstrates Clinically Meaningful Prevention of Weight Rebound and Metabolic Benefits After Stopping GLP-1 Therapy ...
PipelineReview.com4h

Pilatus Biosciences Announces Clinical Trial Collaboration with Roche to Evaluate PLT012 in First-in-Human Study in Hepatocellular Carcinoma

EPALINGES, Switzerland I August 13, 2025 I Pilatus Biosciences, Inc., a biopharmaceutical company developing novel metabolic checkpoint immunotherapies for ...
PipelineReview.com4h

ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy

CULVER CITY, CA, USA I Augus 13, 2025 I ImmunityBio (NASDAQ: IBRX), a leading immunotherapy company, announced today early findings from its QUILT-106 Phase I ...
PipelineReview.com4h

Telitacicept Meets Primary Endpoint in Phase III Trial for Primary Sjögren’s Syndrome in China

YANTAI, China I August 13, 2025 I On August 13th, Remegen (688331.SH/09995.HK) announced that its global first-in-class BLyS (BAFF)/APRIL dual-target ...
PipelineReview.com4h

Apertura Gene Therapy Licenses Blood-Brain Barrier-Penetrant AAV Capsid to Multiple Partners Advancing Central Nervous System Treatments

NEW YORK, NY, USA I August 13, 2025 I Apertura Gene Therapy, a biotechnology company focused on innovative gene therapy solutions announced several licensing ...
PipelineReview.com4h

Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection

SOUTH SAN FRANCISCO, CA, USA I August 13, 2025 I Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on ...
PipelineReview.com9h

Abcentra LLC Announces First Patient Dosed in Phase 2b “FORTIFY” Clinical Trial Evaluating Orticumab in Patients with Cardiovascular Disease

LOS ANGELES, CA, USA I August 12, 2025 I Abcentra LLC, a clinical-stage biopharmaceutical company pioneering targeted therapies for cardiovascular ...
PipelineReview.com9h

Marea Therapeutics Enrolls First Participant in Phase 1 Clinical Study Evaluating MAR002 for Acromegaly

SOUTH SAN FRANCISCO, CA, USA I August 12, 2025 I Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human ...
PipelineReview.com9h

Sen-Jam Pharmaceutical Positions SJP-002C as a Transformative Complement to GLP-1 Therapies and a Standalone Solution for MASH

HUNTINGTON, NY, USA I August 12, 2025 I Sen-Jam Pharmaceutical today announced significant progress in advancing its innovative immuno-regulator platform ...
PipelineReview.com9h

FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung ...
PipelineReview.com9h

Daewoong Therapeutics Microneedle Patch Achieves Best-in-Class Bioavailability, Proving the Strength of Its Drug-Delivery Platform

SEOUL, South Korea I August 13, 2025 I Daewoong Pharmaceutical (Co-CEOs Seong-Soo Park and Chang-Jae Lee) and Daewoong Therapeutics (CEO Bok-Ki Kang) ...